The latest from TV, Radio, and Newspapers

Add a news source

Are we missing a Kenilworth news source? Let us know!

Kenilworth Newswire

Kenilworth Newswire

Comprehensive Real-Time News Feed for Kenilworth, NJ.

Results 1 - 20 of 171 in Kenilworth, NJ

  1. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Monday Nov 12 | Business Wire

    ... BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review )--AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administrati... )--AECOM (NYSE:ACM), ...

    Comment?

  2. Us Fda Accepts Regulatory Submission For Lynparza (olaparib)...Read the original story w/Photo

    Monday Nov 12 | TriCities.com

    US FDA Accepts Regulatory Submission For LYNPARZA Maintenance Therapy in Newly-Diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review WILMINGTON, Del.-- --Nov 12, 2018--AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced that the US Food and Drug Administration has accepted a supplemental New Drug Application and granted priority review for the approval of LYNPARZA as a maintenance treatment in patients with newly-diagnosed, BRCA -mutated advanced ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act date is set for the first quarter of 2019.

    Comment?

  3. FDA Accepts Regulatory Submission for LYNPARZA (olaparib) Maintenance ...Read the original story w/Photo

    Monday Nov 12 | TriCities.com

    ... Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review KENILWORTH, N.J.--(BUSINESS WIRE)--Nov 12, 2018--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today ...

    Comment?

  4. FDA Approves Merck's KEYTRUDA (pembrolizumab) for the Treatment of...Read the original story w/Photo

    Friday Nov 9 | TriCities.com

    FDA Approves Merck's KEYTRUDAA for the Treatment of Patients with Hepatocellular Carcinoma Who Have Been Previously Treated with Sorafenib KENILWORTH, N.J.-- --Nov 9, 2018--Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response.

    Comment?

  5. New Data from Investigational Study of LENVIMA (lenvatinib) and...Read the original story w/Photo

    Friday Nov 9 | TriCities.com

    New Data from Investigational Study of LENVIMAA and KEYTRUDAA Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting TOKYO & KENILWORTH, N.J.-- --Nov 9, 2018--Eisai Co., Ltd. and Merck , known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA A , an orally available kinase inhibitor discovered by Eisai, in combination with Merck's anti-PD-1 therapy KEYTRUDA A in three different tumor types - metastatic non-small cell lung cancer , metastatic melanoma and metastatic urothelial carcinoma .

    Comment?

  6. Teacher charged with threatening school said he would 'shoot up the place,' cops sayRead the original story w/Photo

    Thursday Nov 8 | The Jersey Journal

    The faculty member at a Cranford school who was arrested last week for allegedly making terroristic threats against the school where he works will undergo a court-ordered mental health evaluation. On Thursday, Matthew Acosta, 33, of Kenilworth, who works at Orange Avenue School, appeared in front of State Superior Court Judge Daniel R. Lindemann for a detention hearing.

    Comment?

  7. Early Phase 1 Data from Merck's Oncology Pipeline for Investigational ...Read the original story w/Photo

    Wednesday Nov 7 | TriCities.com

    Early Phase 1 Data from Merck's Oncology Pipeline for Investigational Anti-LAG-3 Therapy and Anti-TIGIT Therapy to Be Presented at SITC's 33rd Annual Meeting KENILWORTH, N.J.-- --Nov 7, 2018--Merck , known as MSD outside the United States and Canada, today announced the first presentations of preliminary safety and efficacy data from Phase 1/2 dose finding studies for the company's investigational anti-LAG-3 therapy and anti-TIGIT therapy in patients with advanced solid tumors. LAG-3 and TIGIT are negative immune regulators and play different roles in downregulating the immune response.

    Comment?

  8. Faculty member charged with threatening schoolRead the original story w/Photo

    Sunday Nov 4 | WKXW-FM Trenton

    Matthew Acosta, 33, of Kenilworth was charged by Cranford Police for making the threat against the Orange Avenue School, a middle school in Cranford. Acosta was taken into custody on Friday after authorities were alerted to the threat.

    Comment?

  9. classroom chairs blackboard chalkboard school thinkstock photoRead the original story w/Photo

    Sunday Nov 4 | NJ.com

    A faculty member at a Cranford school has been arrested for making terroristic threats against the campus, according to police. Matthew Acosta, of Kenilworth, faces charges of third degree terroristic threats and risking widespread injury or damage.

    Comment?

  10. Aldene Park Play Surface To Be ReplacedRead the original story w/Photo

    Saturday Nov 3 | Roselle Park News

    The replacement of the rubber play surface at Aldene Park passed a necessary hurdle Thursday night when council awarded the project to Picerno-Giordano Construction, LLC out of Kenilworth at a budget of $117,150.01. $25,470 will be paid through the Union County Leveling The Playing Fields Grant which was awarded in March of this year .

    Comment?

  11. Merck posts global sales of $11B in third quarterRead the original story w/Photo

    Thursday Oct 25 | Fairfield Citizen-News

    This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck & Co. reports earnings Thursday, Oct. 25. FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck & Co.

    Comment?

  12. 'Super' pooper pleads guilty to loads of troubleRead the original story w/Photo

    Wednesday Oct 24 | New York Daily News

    Thomas Tramaglini, a Kenilworth schools superintendent, was arrested on charges of lewdness and public urination/defecation in Holmdel, New Jersey on Mon., April 30, 2018. Tramaglini defecated on a high school track and football field on a daily basis.

    Comment?

  13. It's true! Superintendent pleads guilty to defecating on school propertyRead the original story w/Photo

    Wednesday Oct 24 | WKXW-FM Trenton

    The former Kenilworth schools superintendent has admitted to defecating under the bleachers near a high school track because of a medical condition. Thomas Tramaglini, 42, was arrested on May 1 and charged with lewdness, littering and defecating in public after a Holmdel High School employee investigated a report of human feces being found on or near the track on a daily basis.

    Comment?

  14. Ex-superintendent pleads guilty, admits pooping on school groundsRead the original story w/Photo

    Wednesday Oct 24 | PennLive.com

    ... fine and court costs. Prosecutors agreed to dismiss charges of lewdness and littering. Tramaglini, the former Kenilworth school superintendent, made headlines around the world after police announced he had been arrested and accused of defecating at ...

    Comment?

  15. Lynparza Phase III Solo-1 results show improved outcome for patients...Read the original story w/Photo

    Monday Oct 22 | Medical News

    AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA -mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy. Results of the trial confirm the statistically significant and clinically meaningful improvement in progression-free survival for LYNPARZA compared to placebo, reducing the risk of disease progression or death by 70% .

    Comment?

  16. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Sunday Oct 21 | Business Wire

    ... 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer )--AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., (Merck: known as MSD outside the US and Canada) today announced detailed results from the Phase III SOLO-... SOLO-1 ...

    Comment?

  17. Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2018 CongressRead the original story

    Oct 10, 2018 | Digital Post Production

    ... renal cell carcinoma, and three presentations for eribulin. In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization ...

    Comment?

  18. BrickbatsRead the original story w/Photo

    Oct 1, 2018 | Reason Magazine

    ... by a local TV station found the hospital still has a fly problem, with traps in the hallways and patient rooms. Kenilworth, New Jersey, schools superintendent Thomas Tramaglini has been charged with public defecation, lewdness, and littering after ...

    Comment?

  19. Merck CEO Ken Frazier will stay on past 2019 as board gets rid of mandatory retirement policyRead the original story w/Photo

    Sep 26, 2018 | Philly.com

    Instead, the Kenilworth, N.J., pharmaceutical company announced that its board has done away with a policy mandating the chief executive's retirement at that age. Frazier, who grew up in North Philly, is now planning to remain in the job beyond December 2019.

    Comment?

  20. PeptiDream Announces Drug Discovery and Development Agreement with Santen PharmaceuticalRead the original story w/Photo

    Sep 25, 2018 | Business Wire

    ... Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck & Co., Inc., Kenilworth, NJ, USA, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, Asahi Kasei, Janssen, and Bayer all of which are active and ...

    Comment?

Kenilworth Job Listings
View or post Kenilworth job listings on Topix.
Kenilworth Real Estate
News, listings, and foreclosures in Kenilworth from Topix.
Kenilworth Mortgages
Find mortgage rates in Kenilworth on Topix.